RESEARCH - Lack of effect of TNF-alpha blockade on circulating adiponectin levels

[Guest guest]

Ann Rheum Dis doi:10.1136/ard.2009.114207

Basic and translational research

Concise report

Lack of effect of TNFá blockade therapy on circulating adiponectin

levels in patients with autoimmune disease: results from two

independent prospective studies

Mike J L s1, ine Watt2, Lynne Cherry2, Welsh2,

Henninger3, Ben A C Dijkmans1,4, Iain B McInnes2, T

Nurmohamed1,4, Naveed Sattar2

+ Author Affiliations

1VU University Medical Center, Amsterdam, The Netherlands

2University of Glasgow, Glasgow, UK

3Merck Serono SA, Geneva, Switzerland

4Jan van Breemen Institute, Amsterdam, The Netherlands

Abstract

Background

Adiponectin is an anti-inflammatory and potentially antiatherogenic

molecule. Some recent reports suggest that tumour necrosis factor á

(TNFá) blockade therapy increases circulating adiponectin levels, but

data are sparse and inconsistent.

Methods

Data from a double-blind placebo controlled study of onercept in 126

patients with psoriatic arthritis (PsA) and from pre- and

post-adalimumab treatment in 171 patients with rheumatoid arthritis

(RA) were used to examine the effect of TNFá blockade therapy on

adiponectin.

Results

Despite expected associations of adiponectin with gender and baseline

high-density lipoprotein cholesterol and triglyceride, adiponectin

levels did not change over time with TNFá blockade therapy in either

group. The mean±SD absolute change in adiponectin levels was -0.23±4.6

ìg/ml in patients with PsA treated with combined onercept 50 mg and

onercept 100 mg (vs placebo, p=0.60) and 0.28±3.23 ìg/ml in patients

with RA treated with adalimumab (vs baseline, p=0.66).

Conclusion

These results do not support a significant effect of TNFá blockade

therapy on circulating adiponectin levels in patients with autoimmune

disease.

http://ard.bmj.com/content/early/2010/06/28/ard.2009.114207.abstract?papetoc

Not an MD